Physician profile
Craig Wierum
NPI 1609867233
$1,312,919.11
in general payments reported to CMS, 2019-2025
41 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284K · 2020: $216K · 2021: $220K · 2022: $171K · 2023: $129K · 2024: $119K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $343K · Travel and Lodging: $49K · Food and Beverage: $17K · Consulting Fee: $13K · Education: $40.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $343,290.44 |
| Travel and Lodging | $49,237.74 |
| Food and Beverage | $17,472.83 |
| Consulting Fee | $13,026.25 |
| Education | $40.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $798,937.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $432,239.73 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63,249.62 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $4,247.90 | 2019-2025 | Korlym |
| Mannkind Corporation | $2,015.25 | 2019-2025 | Afrezza |
| Abbvie INC. | $1,875.97 | 2019-2024 | Synthroid |
| Amgen INC. | $1,862.79 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbott Laboratories | $1,548.51 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Insulet Corporation | $871.43 | 2019-2025 | Omnipod |
| Cequr Corporation | $704.98 | 2023-2025 | Cequr Simplicity |
| Medtronic, INC. | $636.69 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Tandem Diabetes Care, INC. | $553.34 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $516.86 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $490.08 | 2023-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $486.96 | 2019-2025 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Wierum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.